Katharina Lueckerath

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/530749/publications.pdf

Version: 2024-02-01

47	1,882	304368 22	264894 42
papers	citations	h-index	g-index

49	49	49	1927
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	First-in-Human Experience of CXCR4-Directed Endoradiotherapy with ¹⁷⁷Lu- and ⁹⁰Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease. Journal of Nuclear Medicine, 2016, 57, 248-251.	2.8	201
2	In vivo molecular imaging of chemokine receptor <scp>CXCR</scp> 4 expression in patients with advanced multiple myeloma. EMBO Molecular Medicine, 2015, 7, 477-487.	3.3	180
3	[⁶⁸Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [¹⁸F]FDG and laboratory values. Theranostics, 2017, 7, 205-212.	4.6	138
4	CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma. Theranostics, 2017, 7, 1589-1597.	4.6	102
5	[68Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer - initial experience. Oncotarget, 2016, 7, 9288-9295.	0.8	92
6	⁶⁸Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Glioblastoma. Theranostics, 2016, 6, 428-434.	4.6	91
7	¹¹C-Methionine-PET in Multiple Myeloma: Correlation with Clinical Parameters and Bone Marrow Involvement. Theranostics, 2016, 6, 254-261.	4.6	80
8	Investigating PSMA-Targeted Radioligand Therapy Efficacy as a Function of Cellular PSMA Levels and Intratumoral PSMA Heterogeneity. Clinical Cancer Research, 2020, 26, 2946-2955.	3.2	71
9	¹¹C-Methionine-PET in Multiple Myeloma: A Combined Study from Two Different Institutions. Theranostics, 2017, 7, 2956-2964.	4.6	63
10	Pitfalls and Common Findings in ⁶⁸Ga-FAPI PET: A Pictorial Analysis. Journal of Nuclear Medicine, 2022, 63, 890-896.	2.8	61
11	Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer. EJNMMI Research, 2018, 8, 96.	1.1	58
12	Runx2 is expressed in human glioma cells and mediates the expression of galectinâ€3. Journal of Neuroscience Research, 2008, 86, 2450-2461.	1.3	56
13	18FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation. Oncotarget, 2014, 5, 7381-7391.	0.8	56
14	Chemokine receptor â€“ Directed imaging and therapy. Methods, 2017, 130, 63-71.	1.9	45
15	Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities. Clinical Cancer Research, 2022, 28, 4346-4353.	3.2	45
16	Immune-Checkpoint Blockade Enhances ²²⁵Ac-PSMA617 Efficacy in a Mouse Model of Prostate Cancer. Journal of Nuclear Medicine, 2021, 62, 228-231.	2.8	44
17	Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy. Oncotarget, 2016, 7, 20033-20040.	0.8	41
18	Establishing ¹⁷⁷Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer. Journal of Nuclear Medicine, 2017, 58, 1786-1792.	2.8	35

#	Article	IF	Citations
19	Tumor-Associated Macrophages in Glioblastoma Multiformeâ€"A Suitable Target for Somatostatin Receptor-Based Imaging and Therapy?. PLoS ONE, 2015, 10, e0122269.	1.1	31
20	Targeting Paraprotein Biosynthesis for Non-Invasive Characterization of Myeloma Biology. PLoS ONE, 2013, 8, e84840.	1.1	28
21	Immune modulation by Fas ligand reverse signaling: lymphocyte proliferation is attenuated by the intracellular Fas ligand domain. Blood, 2011, 117, 519-529.	0.6	26
22	Potential influence of concomitant chemotherapy on <scp>CXCR</scp>4 expression in receptor directed endoradiotherapy. British Journal of Haematology, 2019, 184, 440-443.	1.2	25
23	Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer. International Journal of Molecular Sciences, 2021, 22, 7431.	1.8	25
24	Imaging Inflammation with Positron Emission Tomography. Biomedicines, 2021, 9, 212.	1.4	24
25	Prognostic value of [18F]FDG-PET/CT in multiple myeloma patients before and after allogeneic hematopoietic cell transplantation. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1694-1704.	3.3	23
26	Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer. Journal of Nuclear Medicine, 2021, 62, jnumed.120.256263.	2.8	22
27	Detection Threshold and Reproducibility of ⁶⁸Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer. Journal of Nuclear Medicine, 2018, 59, 1392-1397.	2.8	21
28	68Ga-FAPi-46 diffuse bilateral breast uptake in a patient with cervical cancer after hormonal stimulation. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 924-926.	3.3	19
29	Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell Carcinoma. Journal of Nuclear Medicine, 2022, 63, 396-398.	2.8	18
30	Targeting CXCR4 with [68Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma?. Oncotarget, 2017, 8, 96732-96737.	0.8	17
31	Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted Î±-particle therapy. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 15172-15181.	3.3	16
32	The impact of 177Lu-octreotide therapy on 99mTc-MAG3 clearance is not predictive for late nephropathy. Oncotarget, 0, 7, 41233-41241.	0.8	16
33	Targeted alpha therapy in a systemic mouse model of prostate cancer - a feasibility study. Theranostics, 2020, 10, 2612-2620.	4.6	15
34	Nano-coating protects biofunctional materials. Materials Today, 2012, 15, 394-404.	8.3	14
35	[¹¹C]Methionine emerges as a new biomarker for tracking active myeloma lesions. British Journal of Haematology, 2018, 181, 701-703.	1.2	13
36	PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates. Clinical Cancer Research, 2021, 27, 2050-2060.	3.2	13

#	Article	IF	Citations
37	The gross picture: intraindividual tumour heterogeneity in a patient with nonsecretory multiple myeloma. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1097-1098.	3.3	11
38	Drug and molecular radiotherapy combinations for metastatic castration resistant prostate cancer. Nuclear Medicine and Biology, 2021, 96-97, 101-111.	0.3	10
39	Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy. EJNMMI Research, 2014, 4, 74.	1.1	9
40	Human Organotypic Lung Tumor Models: Suitable For Preclinical 18F-FDG PET-Imaging. PLoS ONE, 2016, 11, e0160282.	1.1	9
41	Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy. EJNMMI Research, 2014, 4, 46.	1.1	8
42	FDG PET/CT Depicts Cutaneous Plasmocytoma. Clinical Nuclear Medicine, 2014, 39, 910-911.	0.7	6
43	[68Ga]Pentixafor: A Novel PET Tracer for Imaging CXCR4 Status in Patients with Multiple Myeloma. Blood, 2014, 124, 2014-2014.	0.6	3
44	Administration Routes for SSTR-/PSMA- and FAP-Directed Theranostic Radioligands in Mice. Journal of Nuclear Medicine, 2022, 63, 1357-1363.	2.8	1
45	Abstract 5345: Heterogeneous tumor PSMA expression represents a resistance mechanism to PSMA-targeted radioligand therapy. , 2020, , .		0
46	717â€…AMG 160, a prostate-specific membrane antigen (PSMA)-targeted BiTE^{Â®}immuno-oncology therapy, is active in models of advanced prostate cancer that are resistant to radioligand therapy. , 2020, , .		0
47	CXCR4 expression of multiple myeloma as a dynamic process: influence of therapeutic agents. Leukemia and Lymphoma, 0, , 1-10.	0.6	0